News | November 08, 2024
Abbott India reports Q2 FY25 standalone PAT at Rs. 358.61 Cr
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Potential of Ayurveda’s contribution in global health system through various innovative practices
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Subscribe To Our Newsletter & Stay Updated
